Development of [⁸⁹Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.

ABSTRACT:

Purpose

Multiple myeloma (MM) is a bone marrow malignancy that remains mostly incurable. Elotuzumab is an FDA-approved therapeutic monoclonal antibody targeted to the cell surface glycoprotein CS1, which is overexpressed in MM cells. Identifying patients who will respond to CS1-targeted treatments such as elotuzumab requires the development of a companion diagnostic to assess the presence of CS1. Here, we evaluated [⁸⁹Zr]DFO-elotuzumab as a novel PET tracer for imaging CS1 expression in preclinical MM models.

Methods

Conjugation of desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) to elotuzumab enabled zirconium-89 radiolabeling. MM.1S-CG cells were intravenously injected in NOD SCID gamma (NSG) mice. Small animal PET imaging with [⁸⁹Zr]DFO-elotuzuma

SUBMITTER: Ghai A 

PROVIDER: S-EPMC8110592 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature